期刊文献+

卡维地洛抗豚鼠再灌注早期心室颤动作用及其机制 被引量:2

Effect and mechanism of carvedilol on ventricular fibrillation at early phase of reperfusion in guinea pig
原文传递
导出
摘要 目的:探讨卡维地洛抗豚鼠再灌注早期心室颤动作用及其机制。方法:利用心肌缺血再灌注损伤模型,研究卡维地洛在0·1、1·0和10·0μmo1/L3个浓度时对再灌注早期心脏去甲肾上腺素(NE)释放及心室颤动发生的影响。结果:①卡维地洛在1·0μmo1/L和10·0μmo1/L时心脏流出液中的NE含量分别为(13·390±7·011)pmol/g心脏组织和(5·004±2·598)pmol/g心脏组织,均显著低于空白对照组(38·670±13·661)pmol/g(P<0·05);②卡维地洛可明显降低再灌注早期心室颤动的发生。结论:缺血再灌注心脏释放的NE在再灌注心律失常的发生中可能起着重要作用,卡维地洛呈浓度依赖性的减少再灌注早期心脏交感神经递质NE释放的作用应是其抗再灌注心律失常心室颤动的作用机制之一。 Objective:To study the effect and mechanism of carvedilol on ventricular fibrillation at early phase of reperfusion in guinea pig. Method: The model of heart reperfusion injury was used to investigate the effect of 0.1.1.0 and 10.0μmol/L carvedilol on cardiac norepinephrine release and ventricular fibrillation at the early phase of reperfusion. Result:①In hearts perfused with 1.0/μmol/L and 10.0 μmol/L carvedilol, the amounts of norepinephrine release were ( 13.390 ± 7. 011 ) pmol/g and ( 5. 004± 2.598) pmol/g, respectively. There were significant differences (all P 〈0.05) when compared with the control group(38. 670 ±13. 661)pmol/g . ②Carvedilol reduced the incidence of ventricular fibrillation significantly ( P 〈0.05). Conclusion:h is suggested that released norepinephrine probably plays an important role in the genesis of reperfusion-induced ventricular fibrillation. The decreasing of norepinephrine release by carvedilol contributes to its antiventricular fibrillation effect at the early phase of reperfusion,in a concentration dependent manner.
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2005年第11期669-671,共3页 Journal of Clinical Cardiology
关键词 心肌再灌注损伤 心室颤动 去甲肾上腺素 卡维地洛 Myocardial reperfusion injury Ventricular fibrillation Norepinephrine Carvedilol
  • 相关文献

参考文献8

  • 1Kurz T,Offner B,Schreieck J,et al. Nonexocytotic noradrenaline release and ventricular fibrillation in ischemic rat hearts. Naunyn Schmiedebergs Arch Pharmacol, 1995,352:491-496.
  • 2Du X J,Riemersma R A,Fox K A A,et al.Propranolol and lidocaine inhibit neural norepinephrine release in hearts with increased extracellular potassium and ischaemia.Circulation,1993,88:1885-1892.
  • 3Cao F,Chen J,Lopez B L,et al. Comparison of bisoprolol ang carvedilol cardioprotection in a rabbit ischemia and reperfusion model. Eur J Pharmacol,2000,406:109-116.
  • 4杨田,沈萍,赵仙先.卡维地洛的药理作用研究进展[J].国外医学(药学分册),2002,29(3):148-151. 被引量:11
  • 5Schomig A. Catecholamines in myocardial ischemia: systemic and cardiac release.Circulation,1990,82(3 Suppl):Ⅱ13-22.
  • 6Naito M,Michelson EL,Kmetzo J J,et al.Failure of anti-arrhythmic drugs to prevent experimental reperfusion ventricular fibrillation.Circulation,1981,63:70-79.
  • 7Sheehan F H, Epstein S E.Effects of calcium channel blocking agents on reperfusion arrhythmias. Am Heart J,1982,103:973-977.
  • 8Kurz T,Richardt D,Gorge B, et al.Differential effects of carvedilol on norepinephrine release in normoxic and ischemic heart. J Cardiovasc Pharmacol,2000,36:96-100.

二级参考文献22

  • 1Kurz T, Richardt D, Gorge B, et al. Differential effects of carvedilol on norepinephrine release in normoxic and ischemic heart[J]. J Cardiovasc Pharmacol, 2000, 36(1):96- 100.
  • 2Lechat P, Chalon S, Cucherat M, et al. Meta-analysis of randomized clinical trials on β-blocker treatment in heart failure[J]. Circulation, 1996, 94(Suppl 1) :1665 - 1668.
  • 3Krum H, Ninio D, MacDonald P. Baseline predictors of tolerability to carvedilol in patients with chronic heart failure [J]. Heart, 2000, 84(6) :615 - 619.
  • 4Doughty RN, Rodger A, Sharpe N, et al. Effects of β-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials[J]. Eur Heart J, 1997, 18(4) :560- 565.
  • 5Bristow MR. Mechanism of action of β-blocking agents in heart failure[J]. Am J Cardiol, 1997, 80(11A) :26L-40L.
  • 6Stoschitzky K, Koshucharova G, Zweiker R, et al. Differing β-blocking effects of carvedilol and metoprolol[J]. Eur J Heart Fail, 2001, 3(3) :343 - 349.
  • 7Colucci WS. Molecular and cellular mechanisms of myocardial failure[J]. Am J Cardiol, 1997, 80(11A): 15L-25L.
  • 8Oettl K, Greilberger J, Zangger K, et al. Radical-scavenging and iron-chelating properties of carvedilol, an antihypertensive drug with antioxidative activity[J]. Biochem Pharmacol, 2001, 62(2) :241 - 248.
  • 9Matsuda Y, Akita H, Terashima M, et al. Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease[J]. Am Heart J, 2000, 140(5):753 - 759.
  • 10Santos DJ, Moreno AJ. Inhibition of heart mitochondrial lipid peroxidation by non-toxic concentrations of carvedilol and its analog BM-910228[J]. Biochem Pharmacol, 2001,61(2): 155 - 164.

共引文献10

同被引文献60

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部